Nektar Therapeutics
NKTRHealthcare|Biotechnology|USA
$70.36
-2.55 (-3.50%)
Tangible Book
$19.55
About
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Stock Price
+180.3%(1Y)
Pipeline Summary
61 total trials26
Phase 1
32
Phase 2
13
Phase 3
0
Phase 4
Completed: 41Terminated: 12Active: 4Withdrawn: 2Recruiting: 2
Active Trials (6)
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT06136741Moderate to Severe Atopic Dermatitis
Phase 2Active
Enrollment: 396 participants
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
NCT05327530Locally Advanced or Metastatic Urothelial Carcinoma
Phase 2Active
Enrollment: 256 participants
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT07690371Moderate-to-Severe Atopic Dermatitis
Phase 3Recruiting
Enrollment: 510 participants
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
NCT06340360Alopecia Areata
Phase 2Active
Enrollment: 94 participants
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
NCT05359211Recurrent Diffuse Large B-Cell Lymphoma
Phase 1Active
Enrollment: 27 participants
BioScore
4/10
Cautious
Ownership
Recent Insider Trades
Zalevsky JonathanSELL
2026-06-305,681 shares @ $70
ROBIN HOWARD WSELL
2026-06-1720,000 shares @ $60.75
Zalevsky JonathanSELL
2026-06-155,538 shares @ $60.71
ROBIN HOWARD WSELL
2026-05-19444 shares @ $65.51
Zalevsky JonathanSELL
2026-05-19199 shares @ $65.51
Recent News
2026-07-03 02:00:52
2026-06-26 21:00:04
2026-06-18 02:01:05
Data last updated: Jul 13, 2026, 12:42 PM